Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1003650

registered interest
date	09/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Antimicrobials: Drug Resistance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to paragraph 6.10 of the UK Five Year Antimicrobial Resistance Strategy 2013 to 2018, published in September 2013, when he plans to publish the evaluation report.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	189732
answer	answer is ministerial correction date of answer 20/11/2018 answer text <p>The United Kingdom Five Year Antimicrobial Resistance Strategy (2013-18) contained a commitment to assess the effectiveness of its implementation plan at the end of the five-year period. The Department commissioned the London School of Hygiene and Tropical Medicine to undertake a full evaluation of the strategy’s implementation.</p><p> </p><p>The evaluation is nearing completion. A final draft report will be submitted to the Department shortly and will be sent out for independent peer-review. The completed report will be put in the public domain next year.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/11/2018 11:27:51 answering member 4067 label Biography information for Steve Brine
tabling member	4433 label Biography information for Thangam Debbonaire

1010543

registered interest
date	20/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Public Health: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the percentage change has been in (a) total funding for NHS England and (b) the local authority public health grant in each year since 2014.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	193486
answer	answer is ministerial correction date of answer 28/11/2018 answer text <p>The local authority public health grant provides funding for health services delivered through local authorities. However it is not the entirety of the funding nor spend for public health services. For example, in addition to the grant there is circa £1.2 billion ringfenced for NHS national public health services within the NHS mandate figures, as well as other Departmental expenditure on vaccines and on grant in aid to Public Health England.</p><p> </p><p>The following table shows the percentage change in total funding for NHS England and the local authority public health grant in each year since 2014:</p><p> </p><table><tbody><tr><td><p> </p></td><td><p>NHS England funding increase %</p></td><td><p>Public health grant increase %</p></td></tr><tr><td><p>2014-15</p></td><td><p>3.6%</p></td><td><p>5.0%</p></td></tr><tr><td><p>2015-16</p></td><td><p>3.3%</p></td><td><p>24%*</p></td></tr><tr><td><p>2016-17</p></td><td><p>5.4%</p></td><td><p>-2.2%</p></td></tr><tr><td><p>2017-18</p></td><td><p>3.6%</p></td><td><p>-2.5%**</p></td></tr><tr><td><p>2018-19</p></td><td><p>4.6%</p></td><td><p>-2.6%</p></td></tr></tbody></table><p><br>Notes:</p><p>* End year allocation for 2015-16 including the transfer in October 2015 of funding from NHS England to local authorities for commissioning services for children aged 0 - 5.</p><p>** Figures from 2017-18 includes funding retained by 10 Greater Manchester local authorities as part of a business rate pilot, not allocated via a grant.</p><p> </p><p>The total Department of Health and Social Care Departmental Expenditure Limit for 2018-19 was £128.4 billion. 2.5 % was allocated to the local authority public health grant in 2018-19.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 193487 question first answered 28/11/2018 17:38:47 answering member 4067 label Biography information for Steve Brine
tabling member	4433 label Biography information for Thangam Debbonaire

750163

registered interest
date	10/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	GP Surgeries: Repairs and Maintenance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has carried out to ensure that the proposed £1,000 financial assistance offered to GP practices which accept the full repairing lease contract will be sufficient to cover the legal and survey work associated with those leases.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	4033
answer	answer is ministerial correction date of answer 13/07/2017 answer text <p>The £1,000 + VAT offered to general practitioner practices is intended to assist with the legal fees associated with documenting a lease. The calculation is based on the fact that the ‘template’ lease has already been negotiated and agreed with NHS Property Services and the British Medical Association, which minimises negotiations with practices.</p><p> </p><p>The nature of lease – either Full Repairing and Insuring or Internal Repairs – determines the level of reimbursement for the current market rent. This includes both the lease rent and an element for upkeep of the tenanted areas. This is set out in the Premises Costs Directions 2013.</p><p> </p><p>Ultimately, it is for the landlord and tenant to agree the terms of any lease to suit their specific circumstances.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 4036 question first answered 13/07/2017 13:05:44 answering member 4067 label Biography information for Steve Brine
tabling member	4433 label Biography information for Thangam Debbonaire

750164

registered interest
date	10/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	General Practitioners: Finance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans he has to review the Carr-Hill funding formula for GP practices with atypical populations.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	4034
answer	answer is ministerial correction date of answer 13/07/2017 answer text <p>NHS England recognises that atypical practices with a significantly skewed patient population will not necessarily have their workload reflected through the Carr-Hill Formula. It is for this reason that NHS England is exploring the additional demands on atypical practices, testing out in the first instance, the experiences of practices that serve university populations, practices with significant number of non-English speaking patients, and practices operating within remote or isolated areas.</p><p> </p><p>Commissioner guidance was published in December 2016 and further analysis of the workload implications is being undertaken.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 13/07/2017 11:47:14 answering member 4067 label Biography information for Steve Brine
tabling member	4433 label Biography information for Thangam Debbonaire

750166

registered interest
date	10/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	GP Surgeries: Repairs and Maintenance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the effect on GP funding of the proposed full repairing leases offered to GP surgeries.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	4036
answer	answer is ministerial correction date of answer 13/07/2017 answer text <p>The £1,000 + VAT offered to general practitioner practices is intended to assist with the legal fees associated with documenting a lease. The calculation is based on the fact that the ‘template’ lease has already been negotiated and agreed with NHS Property Services and the British Medical Association, which minimises negotiations with practices.</p><p> </p><p>The nature of lease – either Full Repairing and Insuring or Internal Repairs – determines the level of reimbursement for the current market rent. This includes both the lease rent and an element for upkeep of the tenanted areas. This is set out in the Premises Costs Directions 2013.</p><p> </p><p>Ultimately, it is for the landlord and tenant to agree the terms of any lease to suit their specific circumstances.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 4033 question first answered 13/07/2017 13:05:44 answering member 4067 label Biography information for Steve Brine
tabling member	4433 label Biography information for Thangam Debbonaire

750926

registered interest
date	11/07/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Breast Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what proportion of drugs for the treatment and post-treatment needs of breast cancer patients contain lactose; and what provision is made for breast cancer patients who are intolerant or allergic to lactose.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	4161
answer	answer is ministerial correction date of answer 17/07/2017 answer text <p>Lactose (milk sugar) is commonly used as a diluent in solid oral dosage forms such as tablets and capsules; however is rarely present in oral liquid presentations or parenteral dosage forms, such as injections. While no list of “lactose-free” medicines is maintained, the presence or absence of lactose in any licensed medicine, including those for breast cancer, can be readily identified.</p><p> </p><p>Where a medicine contains lactose, this is highlighted, together with the quantity of lactose, within the Summary of Product Characteristics. The package leaflet for that medicine will also highlight in qualitative terms whether the medicine contains lactose. The package leaflet is provided with each pack of medicine sold or dispensed in the United Kingdom.</p><p> </p><p>The British National Formulary, a standard medical text in the UK, advises that the lactose content in most medicines is too small to cause problems in most lactose-intolerant patients. However, in patients with severe lactose intolerance, lactose content should be determined before prescribing especially if they are taking several products containing lactose.</p><p> </p><p>Clinicians prescribe the medicines and drugs that are most appropriate for their patient, taking into account all relevant factors and guidance. The Medicines and Healthcare products Regulatory Agency, which is responsible for the regulation of medicines in the UK, will help prescribers to establish the availability of a lactose free version of any particular medicine.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 17/07/2017 15:49:05 answering member 4067 label Biography information for Steve Brine
tabling member	4433 label Biography information for Thangam Debbonaire

759725

registered interest
date	12/09/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Benzodiazepines
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what data his Department collected on benzodiazepine dependence relating to 2016.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	10122
answer	answer is ministerial correction date of answer 09/10/2017 answer text <p>Data specific to this question is not held centrally.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 09/10/2017 11:28:10 answering member 4067 label Biography information for Steve Brine
tabling member	4433 label Biography information for Thangam Debbonaire

772219

registered interest
date	17/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Motor Neurone Disease: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans his Department has to assess the (a) clinical benefit and (b) value for money of Endaravone in extending the lifespan of people with motor neurone disease.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	108151
answer	answer is ministerial correction date of answer 25/10/2017 answer text <p>We have assumed the Hon. Member is referring to edaravone (Radicava). Edaravone is not currently licensed or under assessment within the European Union for any indication and the Department therefore has no such plans. If the manufacturer seeks a marketing authorisation for edaravone in the United Kingdom or EU, it will be assessed for safety, efficacy and quality through the established licensing process and then considered through the topic selection process for possible assessment of clinical and cost effectiveness by the National Institute for Health and Care Excellence (NICE).</p><p> </p><p>Where a drug or treatment has not been appraised by NICE, funding decisions should be made by the relevant National Health Service commissioner, based on an assessment of the available evidence and on the basis of an individual patient’s clinical circumstances.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 25/10/2017 15:57:33 answering member 4067 label Biography information for Steve Brine
tabling member	4433 label Biography information for Thangam Debbonaire

805975

registered interest
date	13/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of whether the UK not being part of the Clinical Trials Regulation coming into effect in 2019 will be able to take part in such trials after the UK leaves the EU.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	119185
answer	answer is ministerial correction date of answer 21/12/2017 answer text <p>The Government values the strong collaborative partnerships that we have across the European Union in the areas of science, research and innovation, and as part of Exit negotiations is working to ensure that we have the best possible environment in which to support clinical trials and new medicines after we leave the EU.</p><p> </p><p>In the United Kingdom, the Medicines and Healthcare products Regulatory Agency, Health Research Authority, ethics services, National Institute for Health Research and National Health Service have been working towards implementation of the new European Clinical Trials Regulation (CTR) since it was agreed in 2014. The application date of the CTR across the EU will be set by the European Commission. The current regulatory approval legislation will stay in place until such time as any changes are needed so there will be no interruption in UK clinical trials approval.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 119186 question first answered 21/12/2017 17:02:31 answering member 4067 label Biography information for Steve Brine
tabling member	4433 label Biography information for Thangam Debbonaire

805976

registered interest
date	13/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Clinical Trials: EU Law
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of the legislation that will be required in the UK to ensure that the UK becomes compatible with the EU Clinical Trials Regulation coming into force in 2019.
tabling member constituency	Bristol West
tabling member printed	Thangam Debbonaire
uin	119186
answer	answer is ministerial correction date of answer 21/12/2017 answer text <p>The Government values the strong collaborative partnerships that we have across the European Union in the areas of science, research and innovation, and as part of Exit negotiations is working to ensure that we have the best possible environment in which to support clinical trials and new medicines after we leave the EU.</p><p> </p><p>In the United Kingdom, the Medicines and Healthcare products Regulatory Agency, Health Research Authority, ethics services, National Institute for Health Research and National Health Service have been working towards implementation of the new European Clinical Trials Regulation (CTR) since it was agreed in 2014. The application date of the CTR across the EU will be set by the European Commission. The current regulatory approval legislation will stay in place until such time as any changes are needed so there will be no interruption in UK clinical trials approval.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 119185 question first answered 21/12/2017 17:02:31 answering member 4067 label Biography information for Steve Brine
tabling member	4433 label Biography information for Thangam Debbonaire